Details for Patent: 11,065,213

Which drugs does patent 11,065,213 protect, and when does it expire?

Patent 11,065,213 protects GOCOVRI and is included in one NDA.

This patent has fourteen patent family members in nine countries.

Summary for Patent: 11,065,213

Title:	Amantadine compositions and preparations thereof
Abstract:	Provided herein are oral pharmaceutical compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, and which have a low level of organic solvent. Provided are also methods of orally administrating a composition comprising amantadine, or a pharmaceutically acceptable salt thereof, to a subject, which has reduced gastrointestinal side effects or sleep disturbances. Further provided are extended release oral compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, that are suitable for once daily administration.
Inventor(s):	Gregory T. Went, Timothy J. Fultz, Sangita GHOSH, Natalie McClure
Assignee:	Adamas Pharma LLC
Application Number:	US16/677,431
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,065,213
Patent Claim Types: see list of patent claims	Composition; Formulation; Device; Dosage form;

Drugs Protected by US Patent 11,065,213

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	GOCOVRI	amantadine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	208944-001	Aug 24, 2017		RX	Yes	No	11,065,213		Y
Supernus Pharms	GOCOVRI	amantadine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	208944-002	Aug 24, 2017		RX	Yes	Yes	11,065,213		Y

International Family Members for US Patent 11,065,213

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018320946
Australia	2024205201
Brazil	112020003375
Canada	3072764